Acrux Limited (ACR.AX)
AUD 0.02
(4.35%)
AUD 0.02
(4.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -9.83 Million AUD | -190.09% |
| 2023 | -3.39 Million AUD | 73.85% |
| 2022 | -12.96 Million AUD | 20.21% |
| 2021 | -16.25 Million AUD | -34.56% |
| 2020 | -12.07 Million AUD | 7.03% |
| 2019 | -12.99 Million AUD | -35.92% |
| 2018 | -9.55 Million AUD | -186.54% |
| 2017 | 11.04 Million AUD | -41.46% |
| 2016 | 18.86 Million AUD | 12.25% |
| 2015 | 16.8 Million AUD | -62.74% |
| 2014 | 45.09 Million AUD | 355.1% |
| 2013 | 9.9 Million AUD | 203.12% |
| 2012 | 3.26 Million AUD | -96.08% |
| 2011 | 83.31 Million AUD | 68.61% |
| 2010 | 49.41 Million AUD | 567.3% |
| 2009 | -10.57 Million AUD | -53.22% |
| 2008 | -6.9 Million AUD | 29.9% |
| 2007 | -9.84 Million AUD | 19.91% |
| 2006 | -12.29 Million AUD | -51.77% |
| 2005 | -8.09 Million AUD | -73.11% |
| 2004 | -4.67 Million AUD | 21.62% |
| 2003 | -5.96 Million AUD | -55.59% |
| 2002 | -3.83 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.22 Million AUD | 0.0% |
| 2024 FY | -8.57 Million AUD | -152.95% |
| 2024 Q4 | -5.05 Million AUD | 0.0% |
| 2023 FY | -3.39 Million AUD | 73.85% |
| 2023 Q2 | -4.91 Million AUD | 0.0% |
| 2023 Q4 | 1.52 Million AUD | 0.0% |
| 2022 Q4 | -6.26 Million AUD | 0.0% |
| 2022 Q2 | -6.7 Million AUD | 0.0% |
| 2022 FY | -12.96 Million AUD | 20.21% |
| 2021 Q2 | -7.93 Million AUD | 0.0% |
| 2021 Q4 | -8.31 Million AUD | 0.0% |
| 2021 FY | -16.25 Million AUD | -34.56% |
| 2020 FY | -12.07 Million AUD | 7.03% |
| 2020 Q4 | -6.04 Million AUD | 0.0% |
| 2020 Q2 | -6.03 Million AUD | 0.0% |
| 2019 Q2 | -3.83 Million AUD | 0.0% |
| 2019 Q4 | -7.09 Million AUD | 0.0% |
| 2019 FY | -12.99 Million AUD | -35.92% |
| 2018 Q2 | -5.01 Million AUD | 0.0% |
| 2018 FY | -9.55 Million AUD | -186.54% |
| 2018 Q4 | -4.54 Million AUD | 0.0% |
| 2017 Q2 | 8.75 Million AUD | 0.0% |
| 2017 FY | 11.04 Million AUD | -41.46% |
| 2017 Q4 | 2.29 Million AUD | 0.0% |
| 2016 FY | 18.86 Million AUD | 12.25% |
| 2016 Q2 | 13.06 Million AUD | 0.0% |
| 2016 Q4 | 5.8 Million AUD | 0.0% |
| 2015 Q2 | 9.97 Million AUD | 0.0% |
| 2015 Q4 | 6.83 Million AUD | 0.0% |
| 2015 FY | 16.8 Million AUD | -62.74% |
| 2014 FY | 45.09 Million AUD | 355.1% |
| 2014 Q4 | 6.98 Million AUD | 0.0% |
| 2014 Q2 | 38.11 Million AUD | 0.0% |
| 2013 FY | 9.9 Million AUD | 203.12% |
| 2013 Q4 | 8.48 Million AUD | 0.0% |
| 2013 Q2 | 1.42 Million AUD | 0.0% |
| 2012 Q3 | 817.25 Thousand AUD | 0.0% |
| 2012 FY | 3.26 Million AUD | -96.08% |
| 2012 Q2 | 817.25 Thousand AUD | -96.09% |
| 2012 Q1 | 20.88 Million AUD | 0.0% |
| 2012 Q4 | - AUD | -100.0% |
| 2011 Q4 | - AUD | -100.0% |
| 2011 FY | 83.31 Million AUD | 68.61% |
| 2011 Q1 | 12.47 Million AUD | 0.0% |
| 2011 Q2 | 20.88 Million AUD | 67.49% |
| 2011 Q3 | 20.88 Million AUD | 0.0% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 Q1 | -2.64 Million AUD | 0.0% |
| 2010 Q2 | 12.47 Million AUD | 571.79% |
| 2010 Q3 | 12.47 Million AUD | 0.0% |
| 2010 FY | 49.41 Million AUD | 567.3% |
| 2009 Q1 | -1.72 Million AUD | 0.0% |
| 2009 FY | -10.57 Million AUD | -53.22% |
| 2009 Q2 | -2.64 Million AUD | -53.22% |
| 2009 Q4 | - AUD | 100.0% |
| 2009 Q3 | -2.64 Million AUD | 0.0% |
| 2008 Q4 | - AUD | 100.0% |
| 2008 Q2 | -1.72 Million AUD | 29.9% |
| 2008 Q1 | -2.46 Million AUD | 0.0% |
| 2008 FY | -6.9 Million AUD | 29.9% |
| 2008 Q3 | -1.72 Million AUD | 0.0% |
| 2007 Q4 | - AUD | 100.0% |
| 2007 Q2 | -2.46 Million AUD | 19.91% |
| 2007 Q1 | -3.07 Million AUD | 0.0% |
| 2007 Q3 | -2.46 Million AUD | 0.0% |
| 2007 FY | -9.84 Million AUD | 19.91% |
| 2006 Q1 | -2.02 Million AUD | 0.0% |
| 2006 Q4 | - AUD | 100.0% |
| 2006 Q3 | -3.07 Million AUD | 0.0% |
| 2006 FY | -12.29 Million AUD | -51.77% |
| 2006 Q2 | -3.07 Million AUD | -51.77% |
| 2005 Q3 | -2.02 Million AUD | 0.0% |
| 2005 Q4 | - AUD | 100.0% |
| 2005 FY | -8.09 Million AUD | -73.11% |
| 2005 Q1 | -1.16 Million AUD | 0.0% |
| 2005 Q2 | -2.02 Million AUD | -73.11% |
| 2004 Q2 | -1.16 Million AUD | 21.62% |
| 2004 Q3 | -1.16 Million AUD | 0.0% |
| 2004 Q4 | - AUD | 100.0% |
| 2004 FY | -4.67 Million AUD | 21.62% |
| 2004 Q1 | -1.49 Million AUD | 0.0% |
| 2003 Q4 | -1.49 Million AUD | 0.0% |
| 2003 FY | -5.96 Million AUD | -55.59% |
| 2003 Q2 | -1.49 Million AUD | -55.59% |
| 2003 Q3 | -1.49 Million AUD | 0.0% |
| 2003 Q1 | -959.13 Thousand AUD | 0.0% |
| 2002 Q3 | -959.13 Thousand AUD | 0.0% |
| 2002 Q2 | -959.13 Thousand AUD | 0.0% |
| 2002 Q4 | -959.13 Thousand AUD | 0.0% |
| 2002 FY | -3.83 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Memphasys Limited | -2.7 Million AUD | -263.683% |
| Race Oncology Limited | -13.38 Million AUD | 26.505% |
| AdAlta Limited | -5.26 Million AUD | -86.902% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -573.965% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -221.114% |
| BTC Health Limited | 1.05 Million AUD | 1031.879% |
| CSL Limited | 5.64 Billion AUD | 100.174% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 78.049% |
| Cynata Therapeutics Limited | -8.8 Million AUD | -11.649% |
| Imugene Limited | -140.93 Million AUD | 93.022% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -378.177% |
| PharmAust Limited | -6.65 Million AUD | -47.688% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -35.987% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 33.101% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 120.009% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -242.197% |
| Nyrada Inc. | -4.56 Million AUD | -115.642% |
| Orthocell Limited | -11.68 Million AUD | 15.813% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 79.17% |
| Starpharma Holdings Limited | -15.15 Million AUD | 35.128% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -65.605% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -36.715% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 49.831% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -122.239% |
| Biome Australia Limited | -1.91 Million AUD | -413.997% |
| Biotron Limited | -5.15 Million AUD | -90.908% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 20.112% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 201.209% |
| Immutep Limited | -44.93 Million AUD | 78.116% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -360.905% |
| Noxopharm Limited | -7.53 Million AUD | -30.511% |
| Patrys Limited | -3.53 Million AUD | -177.863% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -36.841% |
| PYC Therapeutics Limited | -38.85 Million AUD | 74.692% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 60.758% |
| Hexima Limited | -1 Million AUD | -874.87% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 104.352% |
| Nanollose Limited | -1.24 Million AUD | -686.83% |
| Tissue Repair Ltd | -4.87 Million AUD | -101.684% |
| AnteoTech Limited | -11.72 Million AUD | 16.139% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 84.897% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 55.404% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -114.286% |
| Actinogen Medical Limited | -12.83 Million AUD | 23.405% |
| Immuron Limited | -5.8 Million AUD | -69.519% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -73.402% |